RVPH News and Press, Reviva Pharmaceuticals Holdings Inc.

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sam...

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syst...

A look at the top 10 most actives in the United States PicoCELA Inc. (PCLA) rose 192.4% to $0.36 on volume of 821,966,430 shares Vivakor Inc. (VIVK) fell 24.2% to $0.0466 on volume of 515,838,630 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 1.6% to $3.01 on volume of 176,6...

A look at the top 10 most actives in the United States PicoCELA Inc. (PCLA) rose 187.7% to $0.35415 on volume of 767,352,903 shares Vivakor Inc. (VIVK) rose 38.2% to $0.085 on volume of 419,300,053 shares Trinity Biotech plc (TRIB) rose 55.9% to $1.3902 on volume of 168,746,679 shares Dir...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad...

2025-12-16 03:23:50 ET Thesis I am reverting to coverage of Reviva Pharmaceuticals (RVPH), after having covered the company a year ago with a Buy recommendation. The stock has gone down considerably over the past year. The company has informed investors on the long-term effi...

2025-11-13 16:59:09 ET More on Reviva Pharmaceuticals Reviva Pharmaceuticals announces pricing of $9M public offering Reviva Pharmaceuticals announces proposed public offering Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings d...

– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilarox...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syst...